The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Alcoa Buys South32 Aluminum Assets in Up to $5.6 Billion Deal
Alcoa has agreed to buy South32’s bauxite, alumina and...
France have Mbappé but are so much more — and that might make them unbeatable
Jun 30, 2026, 08:13 PM ETEAST RUTHERFORD, N.J. --...
House sinks Rep. Rashida Tlaib’s second war powers resolution on Lebanon
Washington — For a second...